A型肉毒毒素皮内注射治疗玫瑰痤疮持久性红斑及潮红专家共识

doi:10.35541/cjd.20220390

Abstract

Abstract: 【Abstract】 Botulinum toxin A, a type of neurotoxin, is widely used in the field of cosmetic dermatology. Evidence has demonstrated that intradermal injections of botulinum toxin A can improve flushing and persistent erythema in patients with rosacea, while consensus on the treatment concentrations, doses, operation methods, courses, and intervals is still lacking. Based on guidelines for the diagnosis and treatment of rosacea, as well as recent literature and clinical experience of various experts, members of the Rosacea Research Center of Chinese Society of Dermatology and the Rosacea Professional Committee of China Dermatologist Association developed this consensus, aiming to provide scientific and standardized reference for the intradermal injections with botulinum toxin A in the treatment of rosacea.

Key words: Botulinum toxins, type A, Rosacea, Erythema, Flushing, Treatment, Consensus

Rosacea Research Center, Chinese Society of Dermatology, Rosacea Professional Committee, China Dermatologist Association. Expert consensus on intradermal injections with botulinum toxin A for the treatment of flushing and persistent erythema caused by rosacea[J]. Chinese Journal of Dermatology, 2023, 56(1): 16-21.doi:10.35541/cjd.20220390

References ［37］

［1］	Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA［J］. J Drugs Dermatol, 2012,11（12）:e76⁃e79.
［2］	张二佳, 林彤. A型肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 中国麻风皮肤病杂志, 2021,37（9）:610⁃613. doi: 10.12144/zgmfskin202109610.
［3］	曾黛琳, 于波, 吴琳. 肉毒毒素微滴注射治疗玫瑰痤疮的研究进展［J］. 实用皮肤病学杂志, 2021,14（5）:297⁃300. doi: 10.11786/sypfbxzz.1674⁃1293.20210510.
［4］	Bloom BS, Payongayong L, Mourin A, et al. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea［J］. Dermatol Surg, 2015,41 Suppl 1:S9⁃16. doi: 10.1097/DSS. 0000000000000277.
［5］	Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double⁃blind, placebo⁃controlled, split⁃face pilot study in rosacea patients with facial erythema［J］. Dermatol Surg, 2019,45（9）:1155⁃1162. doi: 10. 1097/DSS.0000000000001819.
［6］	Sundaram H, Signorini M, Liew S, et al. Global aesthetics consensus: botulinum toxin type a⁃⁃evidence⁃based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications［J］. Plast Reconstr Surg, 2016,137（3）:518e⁃529e. doi: 10.1097/01.prs. 0000475758.63709.23.
［7］	中华医学会整形外科学分会微创美容专业学组. A型肉毒毒素用于面部医学美容的临床专家共识［J］. 中华整形外科杂志, 2018,34（10）:791⁃795,802. doi: 10.3760/cma.j.issn.1009⁃4598.2018.10.001.
［8］	中国医师协会皮肤科医师分会注射美容亚专业委员会. 肉毒毒素注射在皮肤美容中应用的专家共识［J］. 中国美容医学, 2017,26（8）:3⁃8.
［9］	肉毒毒素治疗应用专家组, 中华医学会神经病学分会帕金森病及运动障碍学组. 中国肉毒毒素治疗应用专家共识［J］. 中华神经科杂志, 2018,51（10）:779⁃786. doi: 10.3760/cma.j.issn.1006⁃7876.2018.10.002.
［10］	Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: The 2017 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2018,78（1）:148⁃155. doi: 10.1016/j.jaad.2017.08.037.
［11］	Thiboutot D, Anderson R, Cook⁃Bolden F, et al. Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee［J］. J Am Acad Dermatol, 2020,82（6）:1501⁃1510. doi: 10.1016/j.jaad.2020.01. 077.
［12］	中华医学会皮肤性病学分会玫瑰痤疮研究中心, 中国医师协会皮肤科医师分会玫瑰痤疮专业委员会. 中国玫瑰痤疮诊疗指南（2021版）［J］. 中华皮肤科杂志, 2021,54（4）:279⁃288. doi: 10.35541/cjd.20201078.
［13］	汪犇, 赵志祥, 简丹, 等. 中国玫瑰痤疮临床特征分析和诊断标准再探讨［J］. 中华皮肤科杂志, 2020,53（9）:675⁃679. doi: 10.35541/cjd.20200376.
［14］	Schaller M, Dirschka T, Lonne⁃Rahm SB, et al. The importance of assessing burning and stinging when managing rosacea: a review［J］. Acta Derm Venereol, 2021,101（10）:adv00584. doi: 10.2340/actadv.v101.356.
［15］	Tan J, Steinhoff M, Bewley A, et al. Characterizing high⁃burden rosacea subjects: a multivariate risk factor analysis from a global survey［J］. J Dermatolog Treat, 2020,31（2）:168⁃174. doi: 10. 1080/09546634.2019.1623368.
［16］	Schwab VD, Sulk M, Seeliger S, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea［J］. J Investig Dermatol Symp Proc, 2011,15（1）:53⁃62. doi: 10.1038/jidsymp.2011.6.
［17］	Drummond PD, Su D. Endothelial and axon reflex vasodilatation to acetylcholine in rosacea⁃affected skin［J］. Arch Dermatol Res, 2012,304（2）:133⁃137. doi: 10.1007/s00403⁃011⁃1177⁃1.
［18］	Báez A, Paleari J, Durán MN, et al. Frey syndrome secondary to submaxillectomy and botulinic treatment［J］. Medicina （B Aires）, 2007,67（5）:478⁃480.
［19］	Khan TT, Herne K, Dayan SH, et al. Facial blanching due to neurotoxins: proposed mechanisms［J］. Dermatol Surg, 2013,39（1 Pt 1）:24⁃29. doi: 10.1111/dsu.12057.
［20］	Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea［J］. F1000Res, 2018,7:1885. doi: 10. 12688/f1000research.16537.1.
［21］	Dressler D, Saberi FA, Barbosa ER. Botulinum toxin: mechanisms of action［J］. Arq Neuropsiquiatr, 2005,63（1）:180⁃185. doi: 10.1590/s0004⁃282x2005000100035.
［22］	Choi JE, Di Nardo A. Skin neurogenic inflammation［J］. Semin Immunopathol, 2018,40（3）:249⁃259. doi: 10.1007/s00281⁃018⁃0675⁃z.
［23］	Kellogg DL Jr, Zhao JL, Wu Y, et al. Nitric oxide and receptors for VIP and PACAP in cutaneous active vasodilation during heat stress in humans［J］. J Appl Physiol （1985）, 2012,113（10）:1512⁃1518. doi: 10.1152/japplphysiol.00859.2012.
［24］	Mascarenhas NL, Wang Z, Chang YL, et al. TRPV4 mediates mast cell activation in cathelicidin⁃induced rosacea inflammation［J］. J Invest Dermatol, 2017,137（4）:972⁃975. doi: 10.1016/j.jid.2016.10.046.
［25］	Wang L, Wang YJ, Hao D, et al. The theranostics role of mast cells in the pathophysiology of rosacea［J］. Front Med （Lausanne）, 2019,6:324. doi: 10.3389/fmed.2019.00324.
［26］	Choi JE, Werbel T, Wang Z, et al. Botulinum toxin blocks mast cells and prevents rosacea like inflammation［J］. J Dermatol Sci, 2019,93（1）:58⁃64. doi: 10.1016/j.jdermsci.2018.12.004.
［27］	Pickett A. Can botulinum toxin cause anaphylaxis after an aesthetic treatment?［J］. Clin Exp Dermatol, 2018,43（5）:599⁃600. doi: 10.1111/ced.13342.
［28］	Gheisari M, Moslemi Haghighi S, Baghani M, et al. Generalized drug eruption with vasculopathic reaction pattern to botulinum toxin injection［J］. Dermatol Ther, 2020,33（6）:e14294. doi: 10.1111/dth.14294.
［29］	Grassegger A. Comment on Tamura et al′s Allergic reaction to botulinum toxin: positive intradermal test［J］. Dermatol Surg, 2009,35（6）:1015. doi: 10.1111/j.1524⁃4725.2009.01176.x.
［30］	Cohen JL, Scuderi N. Safety and Patient Satisfaction of AbobotulinumtoxinA for aesthetic use: a systematic review［J］. Aesthet Surg J, 2017,37（suppl_1）:S32⁃S44. doi: 10.1093/asj/sjx010.
［31］	Wu W. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects［J］. Plast Reconstr Surg, 2015,136（5 Suppl）:92S⁃100S. doi: 10.1097/PRS.000000 0000001827.
［32］	Chen Y, Hua W, Li A, et al. Analysis of facial redness by comparing VISIA（®） from Canfield and CSKIN（®） from Yanyun Technology［J］. Skin Res Technol, 2020,26（5）:696⁃701. doi: 10.1111/srt.12856.
［33］	Papageorgiou P, Clayton W, Norwood S, et al. Treatment of rosacea with intense pulsed light: significant improvement and long⁃lasting results［J］. Br J Dermatol, 2008,159（3）:628⁃632. doi: 10.1111/j.1365⁃2133.2008.08702.x.
［34］	Carruthers J, Carruthers A. The effect of full⁃face broadband light treatments alone and in combination with bilateral crow′s feet Botulinum toxin type A chemodenervation［J］. Dermatol Surg, 2004,30（3）:355⁃366. doi: 10.1111/j.1524⁃4725.2004. 30101.x.
［35］	Khoury JG, Saluja R, Goldman MP. The effect of botulinum toxin type A on full⁃face intense pulsed light treatment: a randomized, double⁃blind, split⁃face study［J］. Dermatol Surg, 2008,34（8）:1062⁃1069. doi: 10.1111/j.1524⁃4725.2008.34207.x.
［36］	Al⁃Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type⁃A in the treatment of rosacea⁃associated erythema and flushing［J］. Dermatol Ther, 2020,33（6）:e13976. doi: 10.1111/dth.13976.
［37］	Anzengruber F, Czernielewski J, Conrad C, et al. Swiss S1 guideline for the treatment of rosacea［J］. J Eur Acad Dermatol Venereol, 2017,31（11）:1775⁃1791. doi: 10.1111/jdv.14349.

[1]	Du Fangzhi, Zhang Xu, Wang Qianqiu. Monkeypox: clinical manifestations, diagnosis, treatment and follow-up [J]. Chinese Journal of Dermatology, 2023, 56(1): 76-81.
[2]	Immunology Group, Chinese Society of Dermatology. Consensus on the whole-process management of atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 56(1): 5-15.
[3]	Dildar·Yasen, Mei Xingxing, Zhou Hui, Chen Xiaohong, Tang Xuhua. Clinical features and prognosis of eight cases of Mycoplasma pneumoniae-induced rash and mucositis [J]. Chinese Journal of Dermatology, 2022, 55(9): 767-771.
[4]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[5]	Wang Lingyan, Pan Jing, Miao Gang, Chang Xiaodan, Jin Qiuzi, Guo Ningning, Zhang Jiayu. Analysis of difficult-to-treat sites in patients with psoriasis who received biological therapy [J]. Chinese Journal of Dermatology, 2022, 55(7): 583-587.
[6]	Lyu Sha, Wang Shuang, Wu Hanfei, Zhang Mingrui, Hu Xin, Li Fuqiu. Research progress in sporotrichosis [J]. Chinese Journal of Dermatology, 2022, 55(7): 629-632.
[7]	Liu Yixuan, Jiang Peiyu, Liu Yunyi, Zhang Jiawen, Tao Meng, Li Min, Xu Yang. Mechanism of neurogenic inflammation and botulinum toxin treatment in rosacea [J]. Chinese Journal of Dermatology, 2022, 55(6): 552-554.
[8]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[9]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[10]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[11]	Song Xiaoting, Liu Bo, Chen Yudi, Zhao Zuotao. Pathophysiological pathogenesis of rosacea [J]. Chinese Journal of Dermatology, 2022, 55(5): 446-449.
[12]	Centre for Urticaria Research, Chinese Society of Dermatology. Guidelines for education of patients with chronic urticaria (2022) [J]. Chinese Journal of Dermatology, 2022, 0(4): 20220305-e20220305.
[13]	Luo Shuaihantian, Long Hai, Lu Qianjin, . Research advances in systemic lupus erythematosus in 2021 [J]. Chinese Journal of Dermatology, 2022, 55(4): 369-372.
[14]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Calcium-based antimicrobial peptide compounds cooling gel for the treatment of atopic dermatitis: a randomized, double-blind controlled clinical study [J]. Chinese Journal of Dermatology, 2022, 55(4): 345-348.
[15]	Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 55(4): 304-307.

Expert consensus on intradermal injections with botulinum toxin A for the treatment of flushing and persistent erythema caused by rosacea

PDF

Knowledge

Abstract

Cite this article

share this article

References ［37］

Related Articles 15

Metrics

Comments

Recommended 10